Answers are grounded in this paper and cite their sources.
Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: